WO2019112327A3 - 세포독성 t 세포 생성방법 및 이의 용도 - Google Patents

세포독성 t 세포 생성방법 및 이의 용도 Download PDF

Info

Publication number
WO2019112327A3
WO2019112327A3 PCT/KR2018/015358 KR2018015358W WO2019112327A3 WO 2019112327 A3 WO2019112327 A3 WO 2019112327A3 KR 2018015358 W KR2018015358 W KR 2018015358W WO 2019112327 A3 WO2019112327 A3 WO 2019112327A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cytotoxic
present
conditioned media
specific memory
Prior art date
Application number
PCT/KR2018/015358
Other languages
English (en)
French (fr)
Other versions
WO2019112327A2 (ko
Inventor
박세호
친잉유
Original Assignee
주식회사 이뮤노맥스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 이뮤노맥스 filed Critical 주식회사 이뮤노맥스
Publication of WO2019112327A2 publication Critical patent/WO2019112327A2/ko
Publication of WO2019112327A3 publication Critical patent/WO2019112327A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

본 발명은 시험관내에서 세포독성 T 세포를 생성하는 방법에 관한 것으로서, 보다 상세하게는 섬유아세포를 배양하여 얻은 조건배지 및 재조합 MHC-I/펩타이드 복합체를 이용한 T 세포 자극을 통하여 항원특이적 기억 세포독성 T 세포를 효율적으로 생성하는 방법에 관한 것이다. 본 발명에 따르면, 섬유아세포를 배양하여 얻은 조건배지의 사용으로 면역체크포인트 분자들의 발현을 억제한 종양특이적인 기억 세포독성 T 세포의 생성 효율을 극대화할 수 있으므로, 이렇게 생성된 세포독성 T 세포를 면역치료, 항종양치료 등 다양한 분야에 응용할 수 있다.
PCT/KR2018/015358 2017-12-06 2018-12-06 세포독성 t 세포 생성방법 및 이의 용도 WO2019112327A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0166609 2017-12-06
KR20170166609 2017-12-06

Publications (2)

Publication Number Publication Date
WO2019112327A2 WO2019112327A2 (ko) 2019-06-13
WO2019112327A3 true WO2019112327A3 (ko) 2019-07-25

Family

ID=66751600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015358 WO2019112327A2 (ko) 2017-12-06 2018-12-06 세포독성 t 세포 생성방법 및 이의 용도

Country Status (2)

Country Link
KR (1) KR102130599B1 (ko)
WO (1) WO2019112327A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062791A2 (en) * 2003-12-20 2005-07-14 Jeffrey Sebastian Utilization of stem cell and fibroblast combined products and nutrients in topical compositions
WO2006005977A1 (en) * 2004-07-09 2006-01-19 Nagy, Norbert Novel method for culturing keratinocytes, melanocytes and fibroblasts for skin grafting
EP2853590A1 (en) * 2012-05-22 2015-04-01 The University of Tokyo Method for producing antigen-specific t cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005062791A2 (en) * 2003-12-20 2005-07-14 Jeffrey Sebastian Utilization of stem cell and fibroblast combined products and nutrients in topical compositions
WO2006005977A1 (en) * 2004-07-09 2006-01-19 Nagy, Norbert Novel method for culturing keratinocytes, melanocytes and fibroblasts for skin grafting
EP2853590A1 (en) * 2012-05-22 2015-04-01 The University of Tokyo Method for producing antigen-specific t cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ASADI, MASOUMEH: "Fibroblast and T cells conditioned media induce maturation dendritic cell and promote T helper immune response", VETERINARY RESEARCH FORUM, 2012, pages 111 - 118, XP055628006 *
LATOUCHE, JEAN-BAPTISTE: "Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells", NATURE BIOTECHNOLOGY, 18 April 2000 (2000-04-18), pages 405 - 409, XP002191046, doi:10.1038/74455 *
QIN, YINGYU: "Embryonic fibroblasts promote antitumor cytotoxic effects of CD 8+ T cells", FRONTIERS IN IMMUNOLOGY, vol. 685, 13 April 2018 (2018-04-13), pages 1 - 10, XP055628011 *

Also Published As

Publication number Publication date
KR20190067117A (ko) 2019-06-14
KR102130599B1 (ko) 2020-07-07
WO2019112327A2 (ko) 2019-06-13

Similar Documents

Publication Publication Date Title
CY1120039T1 (el) Ογκολυτικοι αδενοϊικοι φορεις και μεθοδοι και χρησεις οι οποιες σχετιζονται με αυτους
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
EP4253401A3 (en) Personalized immunotherapy against several neuronal and brain tumors
MX2015012450A (es) Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2018217064A3 (ko) 형질전환된 t세포를 이용한 자연살해세포의 배양방법
PH12016500949B1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
RU2014148136A (ru) Композиции т-клеток с недостаточностью рецепторов т-клеток
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TN2012000437A1 (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MX342995B (es) Métodos de generar células asesinas naturales.
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
WO2019002512A3 (en) GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
MX2022002143A (es) Celulas inmunitarias para terapias celulares adoptivas.
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
MX2022012990A (es) Proceso para generar células t autólogas modificadas genéticamente.
AU2018276376A1 (en) Cell culture methods
NZ729729A (en) Production of fully processed and functional factor x in a furin-secreting mammalian expression system
WO2019112327A3 (ko) 세포독성 t 세포 생성방법 및 이의 용도
WO2018152446A3 (en) Cell-penetrating atf5 polypeptides and uses thereof
MY186581A (en) Technology for efficient activation of nkt cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18886530

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18886530

Country of ref document: EP

Kind code of ref document: A2